Search in:

Expert Opinion on Biological Therapy Volume 9, 2009 - Issue 2

Submit an article Journal homepage

170

Views

CrossRef citations to date

Altmetric

Drug Evaluations

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

Isabelle Wauters Catholic University, University Hospital Gasthuisberg, Respiratory Oncology Unit (Pulmonology) and Leuven Lung Cancer Group, Herestraat 49, B-3000 Leuven, Belgium +32 16 346801; +32 16 346803; [email protected]

, MD &

Johan Vansteenkiste

, MD PhD

Pages 221-230 | Published online: 19 Dec 2008

Cite this article
https://doi.org/10.1517/14712590802652280

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Ludwig H, van Belle S, Barret-Lee, et al. The European Cancer Anaemia Survey (ECAS): A large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293-306
PubMed Web of Science ®Google Scholar
Curt GA. Impact of fatigue on quality of life in oncology patients. Semin Hematol 2000;37 (Suppl 6):14S-7S
PubMed Web of Science ®Google Scholar
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34
PubMed Web of Science ®Google Scholar
Barrett-lee PJ, Ludwig H, Birgegard G, et al. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology 2006;70:34-48
PubMed Web of Science ®Google Scholar
Cascinu S, Fedeli A, Del Ferro, et al. Recombinant human erythropoietin treatment in cisplatin-associated anemia: a randomized, double-blind trial with placebo. J Clin Oncol 1994;12:1058-62
PubMed Web of Science ®Google Scholar
Cazzola M, Messinger D, Battistel V, et al. Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood 1995;86:4446-553
PubMed Web of Science ®Google Scholar
Witzig TE, Silberstein PT, Loprinzi CL, et al. Phase III, randomized, double-blind study of epoetin alfa compared with placebo in anemic patients receiving chemotherapy. J Clin Oncol 2004;22:2606-17
Google Scholar
Egrie JC, Dwyer E, Browne JK, et al. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003;31:290-9
PubMed Web of Science ®Google Scholar
Vansteenkiste J, Wauters I. The use of darbepoetin alfa for the treatment of chemotherapy-induced anaemia. Expert Opin Parmacother 2005;6:429-40
PubMed Web of Science ®Google Scholar
Vansteenkiste J, Pirker R, Massuti B, et al. Double-blind, placebo-controlled, randomized Phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 2002;94:1211-20
PubMed Web of Science ®Google Scholar
Hedenus M, Adriansson M, San MJ, et al. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394-403
PubMed Web of Science ®Google Scholar
Varricchio CG, Sloan JA. The need for and characteristics of randomized, Phase III trials to evaluate symptom management in patients with cancer. J Natl Cancer Inst 2002;94:1184-5
PubMed Web of Science ®Google Scholar
Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002;87:268-76
PubMed Web of Science ®Google Scholar
Kotasek D, Steger G, Faught W, et al. Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003;39:2026-34
PubMed Web of Science ®Google Scholar
Canon JL, Vansteenkiste J, Bodoky G, et al. Randomized, double-blind, active-controlled trial of every-3-week Darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273-84
PubMed Web of Science ®Google Scholar
Justice G, Kessler JF, Jadeja J, et al. A randomized, multicenter study of subcutaneous and intravenous darbepoetin alfa for the treatment of chemotherapy-induced anemia. Ann Oncol 2005;16:1192-8
PubMed Web of Science ®Google Scholar
Glaspy J, Henry D, Patel R, et al. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer 2005;41:1140-9
PubMed Web of Science ®Google Scholar
Glaspy JA, Jadeja JS, Justice G, et al. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer 2003;97:1312-20
PubMed Web of Science ®Google Scholar
Kotasek D, Canon JL, San MJ, et al. Correction/maintenance dosing (front loading) of darbepoetin alfa: final results from a randomized Phase 3 active controlled trial. Blood 2004;104:455A
Web of Science ®Google Scholar
Ludwig H. Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol 2006;53(Suppl):13S-17S
Google Scholar
Auerbach M, Ballard H, Trout JR, et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301-7
PubMed Web of Science ®Google Scholar
Henry DH, Dahl NV, Auerbach M, et al. Intravenous ferric gluconate significantly improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist 2007;12:231-42
PubMed Web of Science ®Google Scholar
Bastit L, Vandebroek A, Altintas S, et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611-8
PubMed Web of Science ®Google Scholar
Pedrazzoli P, Farris A, Del Prete, et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alfa. J Clin Oncol 2008;26:1619-25
PubMed Web of Science ®Google Scholar
Bokemeyer C, Aapro MS, Courdi A, et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258-70
PubMed Web of Science ®Google Scholar
Aapro MS, Link H. September 2007 update on EORTC guidelines and anemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33-6
PubMed Web of Science ®Google Scholar
Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 2008;26:132-49
PubMed Web of Science ®Google Scholar
Crawford J, Cella D, Cleeland CS, et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-95
PubMed Web of Science ®Google Scholar
Vaupel P. Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis. Oncologist 2008;13(Suppl 3):21-6
PubMed Web of Science ®Google Scholar
Caro JJ, Salas M, Ward A, Goss G. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214-21
PubMed Web of Science ®Google Scholar
Watine J, Bouarioua N. Anemia as an independent prognostic factor for survival in patients with cancer. Cancer 2002;94:2793-7
PubMedGoogle Scholar
Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60
PubMed Web of Science ®Google Scholar
Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960-72
PubMed Web of Science ®Google Scholar
ODAC-FDA: ODAC-FDA briefing document on Erythropoiesis Stimulating Agents; 2008
Google Scholar
Overgaard J, Hoff CM, Hansen HS, et al. Randomized study of the importance of Novel Erythropoiesis Stimulating Protein (Aranesp®) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC) – the Danish Head and Neck Cancer Group DAHANCA 10 randomized trial. Eur J Cancer 2007;5(Suppl):7
Web of Science ®Google Scholar
Smith RE, Aapro MS, Ludwig H, et al. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 2008;26:1040-50
PubMed Web of Science ®Google Scholar
Wright JR, Ung YC, Julian JA, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027-32
PubMed Web of Science ®Google Scholar
Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. J Natl Cancer Inst 2005;97:489-98
PubMed Web of Science ®Google Scholar
Bohlius J, Wilson J, Seidenfeld J, et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708-14
PubMed Web of Science ®Google Scholar
Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74
PubMed Web of Science ®Google Scholar
Grote T, Yeilding AL, Castillo R, et al. Efficacy and safety analysis of epoetin alfa in patients with small cell lung cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2005;23:9377-86
PubMed Web of Science ®Google Scholar
Pirker R, Ramlau R, Schuette W, et al. Safety and efficacy of darbepoetin alfa in previously untreated extensive stage small cell lung cancer treated with platinum plus etoposide. J Clin Oncol 2008;26:2342-9
PubMed Web of Science ®Google Scholar
Aapro M, Leonard RC, Barnadas A, et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 2008;26:592-8
PubMed Web of Science ®Google Scholar
Hedenus M, Vansteenkiste J, Kotasek D, et al. Darbepoetin alfa for the treatment of chemotherapy-induced anemia: disease progression and survival analysis from 4 randomized, double-blind, placebo-controlled trials. J Clin Oncol 2005;23:6941-8
PubMed Web of Science ®Google Scholar
Ross SD, Allen IE, Henry DH, et al. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature. Clin Ther 2006;28:801-31
PubMed Web of Science ®Google Scholar
Seidenfeld J, Piper M, Flamm C, et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst 2001;93:1204-14
PubMed Web of Science ®Google Scholar
Aapro M, Scherhag A, Burger HU. Effect of treatment with epoetin-β on survival, tumour progression and thromboembolic events in patients with cancer: an updated meta-analysis of 12 randomised controlled studies including 2301 patients. Br J Cancer 2008;99:14-22
PubMed Web of Science ®Google Scholar
Henke M, Mattern D, Pepe M, et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings? J Clin Oncol 2006;24:4708-13
PubMed Web of Science ®Google Scholar
Elliott S, Busse L, Bass MB, et al. Anti-Epo receptor antibodies do not predict Epo receptor expression. Blood 2006;107:1892-5
PubMed Web of Science ®Google Scholar
Aapro MS, Birgegard G, Bokemeyer C, et al. Erythropoietins should be used according to guidelines. Lancet Oncol 2008;9:412-3
PubMed Web of Science ®Google Scholar
Aapro M, Coiffier B, Dunst J, et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 2006;95:1467-73
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Darbepoetin alfa in the treatment of chemotherapy-induced anaemia

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date